Literature DB >> 16052078

No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa.

Christopher J Gill1, Davidson H Hamer, Jonathon L Simon, Donald M Thea, Lora L Sabin.   

Abstract

Medication adherence is essential to successful treatment of HIV/AIDS. Maintaining high adherence will likely prove a major challenge in Africa -- just as it has in developed nations. Despite early reports suggesting that adherence would not pose a major barrier to treatment success, more recent research shows that adherence rates in Africa are quite variable and often poor. Given the large number of patients whose disease will progress if adherence is suboptimal, research is urgently needed to determine patient-level behavioral barriers to adherence and the most effective and appropriate methods for assessing adherence in African cohorts.

Entities:  

Mesh:

Year:  2005        PMID: 16052078      PMCID: PMC6712424          DOI: 10.1097/01.aids.0000180094.04652.3b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  78 in total

1.  Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.

Authors:  Maria L Ekstrand; Anita Shet; Sara Chandy; Girija Singh; Ranjani Shamsundar; Vidya Madhavan; Shanmugam Saravanan; Elsa Heylen; Nagalingeswaran Kumarasamy
Journal:  Int Health       Date:  2011-03       Impact factor: 2.473

2.  Structural barriers to ART adherence in Southern Africa: Challenges and potential ways forward.

Authors:  A Kagee; R H Remien; A Berkman; S Hoffman; L Campos; L Swartz
Journal:  Glob Public Health       Date:  2011

3.  Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda.

Authors:  Glenn J Wagner; Mary Slaughter; Bonnie Ghosh-Dastidar
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-11-30

Review 4.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

5.  Community-based DOT-HAART accompaniment in an urban resource-poor setting.

Authors:  Maribel Muñoz; Karen Finnegan; Jhon Zeladita; Adolfo Caldas; Eduardo Sanchez; Miriam Callacna; Christian Rojas; Jorge Arevalo; Jose Luis Sebastian; Cesar Bonilla; Jaime Bayona; Sonya Shin
Journal:  AIDS Behav       Date:  2009-04-16

6.  Computer-Based Counseling Program (CARE+ Kenya) to Promote Prevention and HIV Health for People Living With HIV/AIDS: A Randomized Controlled Trial.

Authors:  Ann E Kurth; John E Sidle; Nok Chhun; John A Lizcano; Stephen M Macharia; Meghan M Garcia; Ann Mwangi; Alfred Keter; Abraham M Siika
Journal:  AIDS Educ Prev       Date:  2019-10

7.  Access to antiretroviral therapy for adults and children with HIV infection in developing countries: Horizons studies, 2002-2008.

Authors:  Avina Sarna; Scott Kellerman
Journal:  Public Health Rep       Date:  2010 Mar-Apr       Impact factor: 2.792

8.  Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria.

Authors:  Olurotimi Adejumo; Bibilola Oladeji; Onoja Akpa; Kay Malee; Olusegun Baiyewu; Adesola Ogunniyi; Scott Evans; Baiba Berzins; Babafemi Taiwo
Journal:  Int J STD AIDS       Date:  2015-09-18       Impact factor: 1.359

9.  Predictors of adherence to antiretroviral therapy in rural Zambia.

Authors:  James G Carlucci; Aniset Kamanga; Robb Sheneberger; Bryan E Shepherd; Cathy A Jenkins; John Spurrier; Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2008-04-15       Impact factor: 3.731

10.  Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.

Authors:  Benjamin H Chi; Ronald A Cantrell; Isaac Zulu; Lloyd B Mulenga; Jens W Levy; Bushimbwa C Tambatamba; Stewart Reid; Albert Mwango; Alwyn Mwinga; Marc Bulterys; Michael S Saag; Jeffrey S A Stringer
Journal:  Int J Epidemiol       Date:  2009-02-17       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.